We create minimally invasive medical technology addressing patient needs from diagnosis to therapy.
“We Think Big by Creating Small”
David Harding to Join TransMed7, LLC Business Advisory Board
Portola Valley, CA, January 22, 2018; TransMed7, LLC, today announced the addition of David Harding to its Business Advisory Board (BAB). The TransMed7 BAB is composed of accomplished business experts offering innovative advice and dynamic perspectives that will contribute to the accomplishment of TransMed7’s tactical goals and strategic objectives. These experts represent a carefully selected group of proven innovators, each of whom has already established his or her reputation based on high ethical standards, demonstrated leadership, and a willingness to embrace and support a mission for the good of others. The Members of the BAB provide TransMed7’s Senior Management Team with expanded business perspectives in a constantly changing environment, and each Member brings a focus and particular emphasis on one or more of a number of critical business sectors.
Mr. Harding is currently the Senior Vice-President (SVP) of Corporate Strategy and Business Development at Exact Sciences, a diagnostics company focused on colorectal cancer screening. Prior to this role, he was the Chief Commercial Officer at both T2Biosystems, a company focused on innovative approaches to infectious disease testing, and OvaScience, a fertility-oriented biotech. Previously, Mr. Harding held a variety of business unit leadership positions at Hologic, a global healthcare and diagnostics company, over the course of 10 years, culminating in being named the SVP and General Manager of the $1.2 Billion Women’s Health business unit. Prior to Hologic, he was a partner and associate at McKinsey & Company, where he focused on corporate and commercial strategy. Mr. Harding earned his MBA from the University of Pennsylvania’s Wharton School of Business and his Bachelor of Science in Aerospace Engineering from the University of Southern California.
“We are honored to have David Harding join the internationally recognized leaders of our Business Advisory Board,” commented Eugene H. Vetter, TransMed7 CEO and Chairman of the BAB. “In addition to his unique business perspectives, David brings senior management and operational experience to our organization, which will be integral to TransMed7’s commercial launch of our critically needed, minimally-invasive medical technologies to get them into the hands of clinicians for the benefit of their patients around the world as rapidly as possible.”
“Each of the members of our BAB brings years of successful experience across many of the important industries related to and supportive of TransMed7’s mission,” said Dr. Edgar D. Staren, President of TransMed7 and Executive Chairman of the BAB. “We are grateful that David Harding has kindly expressed his willingness to serve as a member of this illustrious group, and we look forward to benefitting from his and their judgment and counsel.”
In anticipation of 510(k) clearance expected in the first quarter of 2018, TransMed7 is finalizing production and market introduction strategies for its SpeedBird™ soft tissue biopsy product platform and its Concorde™ platform technology for stereotactic and MRI based biopsy procedures, with rollout for both domestic and international sales and distribution. The TransMed7 BAB will provide crucial guidance as TransMed7 continues development of its portfolio of next generation products based on innovative variations of its patented “Zero5” working element. These products include, in addition to the above: Cardinal™, a fine-needle core biopsy device for breast, thyroid, and lymph nodes; and Cygnet™, a novel device designed to establish continued access for intervention including aspiration and biopsy of bone marrow. TransMed7 is also currently developing Martinet™, a revolutionary new minimal access device for complete removal of target tissue.